Sermorelin vs Tesamorelin: How They Differ and What the Evidence Covers
Sermorelin and tesamorelin are often grouped together online. Their regulatory status, trial record and approved use are very different.
Words by the editors ·
Sermorelin and tesamorelin both copy the brain's growth hormone-releasing signal, but they are not interchangeable. Tesamorelin has an FDA-approved label for one narrow use: reducing excess abdominal fat in HIV-infected adults with lipodystrophy.1 Sermorelin has a published record mainly as a diagnostic test and in children with growth hormone deficiency, and no sermorelin label was listed in a DailyMed search on October 20, 2026.4,5 Neither has trial evidence for what most men buy peptides for, such as muscle, sleep or anti-aging.
In brief
- Tesamorelin (EGRIFTA SV) is FDA-approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for weight loss.1
- In a 412-patient trial, visceral fat fell 15.2% with tesamorelin and rose 5.0% with placebo over 26 weeks; the gains faded when treatment stopped in a follow-up trial.2,3
- Sermorelin is a 29 amino acid copy of growth hormone-releasing hormone, studied as a diagnostic test and in children; no sermorelin label was listed in a DailyMed search on October 20, 2026.4,5
- We found no trial of either peptide for muscle, sleep or anti-aging in healthy men, and compounded versions are not FDA-approved.6
How do sermorelin and tesamorelin compare side by side?
| Question | Sermorelin | Tesamorelin |
|---|---|---|
| What it is | A 29 amino acid copy of growth hormone-releasing hormone (GHRH)4 | The 44 amino acid human growth hormone-releasing factor sequence plus a hexenoyl group1 |
| FDA label | None listed in a DailyMed search on October 20, 20265 | EGRIFTA SV, with a prescribing label1 |
| Labeled use | None found | Excess abdominal fat in HIV-infected adults with lipodystrophy; not for weight loss1 |
| Main human evidence | Diagnostic testing and children with idiopathic growth hormone deficiency4 | Randomized placebo-controlled trials in people with HIV and abdominal fat2,3 |
| Compounded versions | Not FDA-approved6 | Not FDA-approved6 |
| Trials for muscle, sleep or anti-aging in healthy men | None found | None found |
What does tesamorelin's label say?
The EGRIFTA SV label describes tesamorelin as a growth hormone-releasing factor analog indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. The label adds that it is not indicated for weight loss, that long-term cardiovascular safety has not been established, and that treatment should be reconsidered in patients who have not had a reduction in visceral fat.1
The dose is a daily subcutaneous injection into the abdomen. The label reports a mean elimination half-life of 8 minutes after a single dose in healthy subjects, so it works by prompting the pituitary rather than by lingering in the blood.1 It lists these cautions:
- Contraindications: disruption of the hypothalamic-pituitary axis, active malignancy, hypersensitivity and pregnancy.1
- Glucose: HbA1c of 6.5% or higher was reached by 5% of tesamorelin patients and 1% of placebo patients by week 26.1
- Injection site reactions: 25% vs 14% on placebo in the first 26 weeks.1
- Fluid retention: edema, joint pain and carpal tunnel syndrome, thought to relate to growth hormone induction.1
- Elevated IGF-1: the effects of prolonged elevation are unknown.1
- Age: no information in patients over 65, and not indicated in pediatric patients.1
What do the tesamorelin trials show?
| Study | Design | Finding |
|---|---|---|
| Falutz 20072 | 412 people with HIV and abdominal fat, 26 weeks, placebo-controlled | Visceral fat -15.2% vs +5.0%; IGF-1 +81.0% vs -5.0%; more withdrawals for adverse events on tesamorelin |
| Falutz 20103 | 404 people with HIV, 6 months then a 12-month extension | Visceral fat -10.9% vs -0.6% at 6 months; improvements were rapidly lost in those who switched to placebo |
| 2026 meta-analysis7 | Five randomized trials | Visceral fat -27.71 cm2, lean body mass +1.42 kg; no significant change in subcutaneous fat or BMI |
These results apply to people with HIV on antiretroviral therapy who have excess abdominal fat. The 2007 trial included mostly men (86%), but nothing in these trials tests tesamorelin in otherwise healthy men.2 The loss of benefit after stopping also means the effect depends on continued use.3
What does the sermorelin evidence cover?
The most detailed sermorelin review covers its use as a diagnostic test for growth hormone deficiency and as injections in children with idiopathic deficiency.4 In adults, the published work we found is small. In 14 men on testosterone who took sermorelin alongside two other peptides, IGF-1 rose from 159.5 to 239.0 ng/mL, but it was a retrospective chart review of a combination, so sermorelin's own effect cannot be separated out.8 For the full picture, see our review of whether sermorelin is worth it, the basics in what sermorelin is, and a comparison with another peptide in sermorelin vs ipamorelin.
Why is the comparison so often misleading online?
Pages that compare the two often blend facts that belong to different evidence tiers. A fat-loss result from a trial in people with HIV is quoted as if it applied to any man, or tesamorelin's approved label is used to lend credibility to compounded sermorelin. The two peptides share a mechanism, which is stimulating the pituitary through the GHRH receptor. Sharing a mechanism does not mean sharing a trial record. A 2026 endocrinology review of growth hormone-axis peptides makes a related point about the gap between clinical evidence and self-administered use.9
A higher IGF-1 level is also a lab marker, not an outcome a man can feel, and the tesamorelin label states that the effects of prolonged IGF-1 elevation are unknown.1
Which one makes sense for whom?
- An HIV-infected adult with excess abdominal fat from lipodystrophy: tesamorelin is the labeled option and has the randomized trials. This is a decision for the treating clinician.
- A man curious about either for muscle, sleep or anti-aging: the evidence we found does not show a benefit for these goals, and a clinician can check whether a medical reason exists first.
- Anyone considering a compounded product: the FDA states compounded drugs are not FDA-approved and have not been reviewed for safety and effectiveness.6
Bottom line
The real difference is not potency but evidence and regulation. Tesamorelin is an approved drug with a defined use, trials and a long list of label cautions. Sermorelin is a related peptide with a thinner, older record and no listed label. Choosing between them for a goal neither has been tested for is a guess, and one to take to a clinician rather than make alone.
Questions
What is the difference between sermorelin and tesamorelin?
Both mimic growth hormone-releasing hormone and prompt the pituitary to release growth hormone. Tesamorelin has an FDA-approved label for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. No sermorelin label was listed in a DailyMed search on October 20, 2026, and sermorelin's published record is mainly diagnostic testing and pediatric use.
Is tesamorelin FDA-approved?
Yes, as EGRIFTA SV, for reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy. The label says it is not indicated for weight loss and that long-term cardiovascular safety has not been established.
Is sermorelin the same as tesamorelin?
No. Sermorelin is a 29 amino acid peptide. Tesamorelin uses the full 44 amino acid sequence of human growth hormone-releasing factor with a hexenoyl group attached, according to its label.
Which is better for muscle or anti-aging?
We found no controlled trial of either for muscle, sleep or anti-aging in healthy men. The tesamorelin trials were in people with HIV and excess abdominal fat.
What are the side effects of tesamorelin?
The label lists injection site reactions (25% vs 14% on placebo), joint pain, muscle pain, swelling, glucose intolerance and hypersensitivity reactions. It is contraindicated in pregnancy, active cancer and disruption of the pituitary axis.
Also in this edition
Part of our guide: Sermorelin: The Complete Guide
Notes
- Theratechnologies. EGRIFTA SV (tesamorelin) prescribing information. DailyMed, U.S. National Library of Medicine.
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. PubMed 18057338.
- Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010. PubMed 20101189.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. PubMed 18031173.
- Sermorelin search. DailyMed, U.S. National Library of Medicine. Searched October 20, 2026.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
- Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026. PubMed 41545261.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018. PubMed 28400207.
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol. 2026. PubMed 42395176.